Featuring perspectives from Dr Farrukh T Awan, Dr Bita Fakhri, Dr Kerry A Rogers and Dr William G Wierda, moderated by Dr Jeff Sharman, including the following topics:
- Introduction (0:00)
- Optimizing First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Jeff Sharman, MD (1:44)
- Emerging Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Combination with Bcl-2 Inhibitors — Kerry A Rogers, MD (25:43)
- Optimal Management of Adverse Events with BTK and Bcl-2 Inhibitors; Considerations for Special Patient Populations — Farrukh T Awan, MD (49:20)
- Integration of Noncovalent BTK Inhibitors into the Management of Relapsed/Refractory CLL — Bita Fakhri, MD, MPH (1:11:52)
- Chimeric Antigen Receptor T-Cell Therapy and Other Novel Strategies for CLL — William G Wierda, MD, PhD (1:35:06)
CME information and select publications
Research To Practice | Oncology Videos